Allied Market Research


Fabry’s Disease Treatment Market

Fabry’s Disease Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report by Distribution Channel and by Medication : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Fabry’s Disease or alpha galactosidase-A deficiency is a rare inherited disorder, as a result of the buildup of particular type of fat, namely globotriaosylceramide inside the body’s cells. It is initiated during childhood, and also shows signs and symptoms, which affects various parts of the human body. The characteristic sign or symptom that is shown by the individual includes the formation of clusters of small, dark red colored spots on the skin surface called as angiokeratomas, concurrent episodes of pain in hands and feet namely acroparasthesias, reduced ability to sweat causing hypohidrosis, and impairment in hearing or hearing loss. Furthermore, the symptoms include problems in the gastrointestinal system, formation of cloudiness or streaks in front part of the eye called as corneal verticillata, and continuous ringing in the ear called as tinnitus. It also induces potentially life threatening complications such as heart attack, kidney problems, and also stroke. The rise in number of the incidences of Fabry’s Disease will help the industry grow in the coming years.

COVID-19 scenario analysis:

Pharmaceutical and biotechnological companies are collaborating with governments, around the globe and are working to address the COVID-19 outbreak, from assisting in the development of vaccines to planning for medicines supply chain challenges. The researchers have innovated around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, the medications such as Hydroxychloroquine have been witnessing dramatic surge in demand for the management of COVID-19. Such increase in the demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Due to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the forecast period.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The increase in R&D of the treatment for Fabry’s disease would help the industry grow in the coming years. Furthermore, the additional benefits given for the drugs which are orphan drugs include tax benefits offered by the government for clinical testing and exemption from the prescription medication fees would boost the market in the near future. Additionally, the researcher or the market leader gets exclusivity for distribution of the medication until patent expires. The supervision over the orphan drugs being strict due to the usage of the therapy over specific population affected from the disease and lesser number of approved drugs due to the associated risks of the complications would help the key leaders gain maximum shares during the forecast period. Moreover, the lesser susceptibility on the approval of the drugs after humongous amount of investment may hinder the growth of the market in the coming years.

The global Fabry’s Disease Treatment market trends are as follows:

New product launches to boost the market

The surge in the product launches for the Fabry’s Disease Treatment will gain attention of the global population toward the awareness of such diseases, thereby propelling the industrial growth. The key leaders are focusing mainly over the research and development of the products for medication of Fabry’s Disease, which is anticipated to help the industry grow during the forecast period. For instance, in July 2019, Takeda launched a new enzyme replacement therapy portfolio for the disorders such as Lysosomal Storage Disorders (LSD), to help the individuals with rare diseases in India. The product launched for Fabry’s Disease was Agalsidase alfa. The market leaders are using strategic planning by focusing on specific region and hence capturing maximum shares in the industry.

Furthermore, the strategic planning adopted by the key leaders include the addition of divisions made especially for R&D of the products which are useful for the cure of rare diseases. For instance, Chielsi in February 2020, launched a separate division for the innovation in the curative medication of the Lysosomal Storage Disorders, which also includes Fabry’s Disease. The increase in the advancement in the medication and its positive results would help the industry grow in the near future.

Longer period of royalty for research will flourish the market

The disease being rare is supervised and surveillance reports are closely checked and reported to the government organizations. The Fabry’s Disease is to be given a therapy of the medication called orphan drugs. These medications are given to restricted patient population having limited approval as drugs, on the basis of the toxicity level and side effects being clinically tested. Furthermore, added benefits are provided to the orphan drugs, due to years of R&D owing to the total spending being very high. These drugs are provided with market exclusivity; also an exclusion from prescription drug fees and government also gives tax benefits for the clinical testing of the drugs.

There is a huge investment in R&D of such rare diseases, and approval of the drugs is also difficult even after clinical trials are carried out. The royalty or the exclusivity is hence an advantage for the key market players and hence is anticipated to boost the industry during the forecast period.

Key benefits of the report:

  • This study presents the analytical depiction of the global Fabry’s Disease treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Fabry’s disease treatment market share.
  • The current market is quantitatively analyzed to highlight the global Fabry’s disease treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global Fabry’s disease treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Fabry’s disease treatment market research report:

  • Which are the leading market players active in the Fabry’s disease treatment market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Fabry’s Disease Treatment Market Report Highlights

Aspects Details
By Distribution Channel
  • E-commerce
  • Drug Store and Pharmacies
  • Others
By Medication
  • Agalsidase beta
  • Agalsidase Alpha
  • Migalstat
  • Antihistamines
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players

Shire, Amicus Therapeutics, Inc., Protalix, Genzyme Corporation, Idorsia Pharmaceuticals Ltd, Biosidus S.A., Neuraltus Pharmaceuticals, Inc.., ISU ABXIS, AVROBIO, Inc., JCR Pharmaceuticals Co., Ltd.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Fabry’s Disease Treatment Market

Global Opportunity Analysis and Industry Forecast, 2023-2032